Drug Type Synthetic peptide |
Synonyms BIO 11006 |
Target |
Mechanism MARCKS inhibitors(Myristoylated alanine-rich C-kinase substrate inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC46H75N13O15 |
InChIKeyKCSNGWMKFYVMKF-HGYIIGRXSA-N |
CAS Registry901117-03-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ewing Sarcoma | Phase 2 | US | 04 Oct 2019 | |
Metastatic osteosarcoma | Phase 2 | US | 04 Oct 2019 | |
Osteosarcoma, Recurrent | Phase 2 | US | 04 Oct 2019 | |
Secondary malignant neoplasm of lung | Phase 2 | US | 04 Oct 2019 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | IN | 01 Feb 2018 | |
Non-small cell lung cancer stage IIIB | Phase 2 | IN | 01 Feb 2018 | |
Respiratory Distress Syndrome, Adult | Phase 2 | US | 05 Aug 2017 | |
Inflammation | Phase 2 | US | 01 Jun 2008 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | US | 01 Jun 2008 |